HomeAI · summaries
Storia in 7 fonti
Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast
Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
- ·
morningstar.com
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
